Literature DB >> 6720257

Antithrombin III in oral contraceptive users and during normotensive pregnancy.

G H Weenink, L H Kahlé, R J Lamping, J W ten Cate, P E Treffers.   

Abstract

Plasma antithrombin III (AT III) was determined in four groups of subjects, by employing an automated chromogenic technique. In 25 women, discontinuing oral contraceptives led to a 9% elevation of AT III, while in 13 women AT III levels fell by 9% after starting with the pill. In 77 normotensive pregnant patients AT III levels were normal during the third trimester and did not differ from control values 6-8 weeks after delivery. Women taking the pill at that time did not have lower AT III levels than those who did not. Furthermore, AT III levels in 414 oral contraceptive users were the same as in 572 controls, when random samples were taken during pill cycle and menstrual cycle. It is concluded that although synthetic estrogens do cause a decrease in AT III levels, this decrease is probably the result of estrogen-induced hemodilution, which may also occur during the normal menstrual cycle. If low dose pills are thrombogenic, mass screening for AT III deficiency will not identify those at risk, with the exception of the rare cases of hereditary AT III deficiency.

Entities:  

Keywords:  Biology; Blood Coagulation Effects; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--side effects; Diseases; Embolism; Examinations And Diagnoses; Family Planning; Hematological Effects--analysis; Hemic System; Laboratory Examinations And Diagnoses; Laboratory Procedures; Oral Contraceptives--side effects; Physiology; Pregnancy; Pregnancy, Third Trimester; Reproduction; Reproductive Control Agents; Thromboembolism; Thrombosis; Vascular Diseases

Mesh:

Substances:

Year:  1984        PMID: 6720257     DOI: 10.3109/00016348409156274

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  2 in total

Review 1.  Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism.

Authors:  S M Bates; J S Ginsberg; S E Straus; H Rekers; D L Sackett
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

2.  To be or not to be a case of heparin resistance.

Authors:  Jibran Durrani; Faizan Malik; Naveed Ali; Syed Imran Mustafa Jafri
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.